Clinical trials: Retention
Opioid Use Disorder
Remotely Observed Methadone Evaluation II
Methadone is an effective treatment for severe opioid use disorder (OUD), but access is limited due to the requirement of daily observed dosing by most opioid treatment programs (OTPs).
- Trial name
- ROME II (NCT06338280)
- Testing
- Sonara
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Sonara Health
Urinary Retention, Neurogenic Bladder
Connected Catheter (C2P) Study for Bladder Management
The objective of this study is to evaluate the safety and essential performance of the C2P System in males with neurogenic lower urinary tract dysfunction (NLUTD), both in an acute clinical setting and an extended period of home…
- Trial name
- NCT03626324
- Testing
- C2P
- Where
- 8 sites in United States
- Volunteers
- 27 people
- Sponsor
- Spinal Singularity
Rheumatoid Arthritis
Study to Describe Real World Drug Retention Rate of the Tocilizumab at One Year
This multicenter, prospective, non-interventional study is designed to obtain an accurate estimation of the drug retention rate of Tocilizumab (TCZ) Subcutaneously (SC) under real-world conditions in participants with moderate to…
- Trial name
- NCT02608112
- Testing
- Methotrexate, Tocilizumab
- Where
- 77 sites in France
- Volunteers
- 291 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
Implementation Study to Describe and Compare Retention Rate and Adherence to Adjuvant Therapy With Ribociclib With and Without Usage of Mobile Application in Patients With HR+ HER2-negative Stage II and III Breast Cancer in Real-world Practice
This study is designed to evaluate the effect of using the application on the adherence of patients with luminal HER2- breast cancer (BC) stage II-III to adjuvant therapy with ribociclib in combination with an aromatase inhibitor…
- Trial name
- IMPULSE (NCT06905301)
- Testing
- Ribociclib, Letrozole, Anastrozole
- Where
- 7 sites in Russia
- Volunteers
- 240 people
- Sponsor
- Novartis Pharmaceuticals
Rheumatoid Arthritis
Retention Rates of Adalimumab, Etanercept and Infliximab as First and Second-Line Biotherapy in Patients With Rheumatoid Arthritis in Daily Practice
To compare retention rates of adalimumab, etanercept and infliximab as first-line biotherapy in rheumatoid arthritis (RA), to determine causes of discontinuation, retention-associated factors, and retention rates of possible…
- Trial name
- MAINTAIN (NCT01692899)
- Volunteers
- 780 people
- Sponsor
- Pfizer
Joint Infection
Study in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Occurring After Total Knee Arthroplasty (TKA)
The purpose of this study is to learn about the safety and effects of PLG0206 for treating periprosthetic joint infections (PJI) in conjunction with the DAIR (debridement, antibiotics and implant retention) surgical procedure for…
- Trial name
- NCT05137314
- Testing
- PLG0206
- Where
- 12 sites in United States
- Volunteers
- 14 people
- Sponsor
- Peptilogics
Prosthetic Joint Infection, Bacterial Infections
Bacteriophage Therapy in First Time Chronic Prosthetic Joint Infections
This study will test the feasibility of a regimen of intraoperative (IO) and intravenous (IV) PhageBank™ bacteriophage therapy in conjunction with a DAIR procedure to cure chronic prosthetic joint infection (PJI) without…
- Trial name
- ACTIVE1 (NCT05269121)
- Testing
- Phage Therapy
- Sponsor
- Adaptive Phage Therapeutics, Inc.
Urinary Retention
Assessment of CymActive™ Catheter Technology for UrinAry ReTention and AcceptancE (The ACCTUATE Study)
The ACCTUATE study: Assessment of CymActive™ Catheter Technology for UrinAry reTention and acceptancE study will evaluate a novel catheter design that addresses the specific needs of male long term catheter users living in the…
- Trial name
- ACCTUATE (NCT05848037)
- Testing
- cymactive™ catheter device (CCD), Foley-type catheter device
- Where
- 5 sites in United Kingdom
- Volunteers
- 6 people
- Sponsor
- Ingenion Medical Limited
Type 2 Diabetes Mellitus (T2DM)
A Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate how fasting and stopping the use of Dulaglutide (LY2189265) affect the amount of food and drink that stays in your stomach after a meal.
- Trial name
- GBGT (NCT07313813)
- Testing
- Dulaglutide
- Where
- Singapore
- Volunteers
- 20 people
- Sponsor
- Eli Lilly and Company
Denture Retention
A Clinical Study to Assess Force Required to Dislodge Upper Denture With and Without Use of a Novel Denture Adhesive
The purpose of this study is to investigate the hold properties of an investigational denture adhesive using an established methodology called the maximum incisal bite force (BF), and Kapur-Olshan (KO) index for denture retention…
- Trial name
- NCT04473521
- Testing
- Investigational denture adhesive cream, Super Poligrip Free
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Psoriasis
Evaluation of Humira Retention Rate in Psoriasis Patients in Daily Practice and Assessment of Work Productivity and Quality of Life
This observational study will document to what extent in daily clinical practice Humira (adalimumab) therapy is continued, interrupted or permanently discontinued during a follow-up period of 2 years.
- Trial name
- NCT01169987
- Volunteers
- 191 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
HIV Infections, HSV-2 Genital Herpes
Retention and Duration of Activity of SPL7013 (VivaGel®) After Vaginal Dosing.
To assess the retention and anti-viral activity (human immunodeficiency virus (HIV) and herpes simplex virus 2 (genital herpes, HSV-2) of SPL7013 in cervicovaginal samples taken up to 24 hours after administration of 3% SPL7013…
- Trial name
- NCT00740584
- Testing
- 3% SPL7013 Gel (VivaGel)
- Where
- Australia
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Starpharma Pty Ltd
Prostatic Hyperplasia
Benefits of Adherence to 5-alpha Reductase Inhibitor Treatment in Men With Enlarged Prostate: An Assessment of Medicare and Medicaid Patients Using the MarketScan Database
Adherence and length of treatment with a 5-alpha reductase inhibitor (5ARI) therapy may be associated with improved clinical outcomes for patients with enlarged prostates (EP) and lower health care related costs.
- Trial name
- NCT01376258
- Testing
- 5ARI
- Volunteers
- 28,903 people
- Sponsor
- GlaxoSmithKline
Benign Prostatic Hyperplasia
Clinical Progression and Costs in Benign Prostatic Hyperplasia Patients Treated With Early Versus Delayed Combination Therapy
In patients with benign prostatic hyperplasia (BPH), combination therapy with an alpha-blocker (AB) and a 5 alpha-reductase inhibitor (5ARI) has been shown to reduce the progression of acute urinary retention (AUR) and the…
- Trial name
- NCT01435954
- Testing
- Early combination therapy, Delayed combination therapy
- Volunteers
- 13,551 people
- Sponsor
- GlaxoSmithKline